Want to see ARWR full AI Analyst Report?
ARWR Stock Chart & Stats
$69.51
$0.33(1.68%)
At close: 4:00 PM EST
$69.51
$0.33(1.68%)
Day’s Range― - ―
52-Week Range$14.30 - $87.83
Previous CloseN/A
Volume680.40K
Average Volume (3M)2.47M
Market Cap
$10.47B
Enterprise Value$8.50K
Total Cash (Recent Filing)$1.78B
Total Debt (Recent Filing)$1.37B
Price to Earnings (P/E)―
Beta2.30
Next Earnings
Aug 06, 2026EPS Estimate
-1.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.14
Shares Outstanding140,857,030
10 Day Avg. Volume2,274,428
30 Day Avg. Volume2,467,049
Financial Highlights & Ratios
PEG Ratio28.34
Price to Book (P/B)9.90
Price to Sales (P/S)5.56
P/FCF Ratio29.41
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$91.00Price Target Upside30.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.18
Revenue Forecast (FY)$447.31M
Bulls Say, Bears Say
Bulls Say
Commercial Launch Momentum & EU ApprovalRegulatory approvals in multiple regions including the EU establish a durable commercial footprint and reduce regulatory expansion risk. Combined with accelerating prescription trends, this supports a growing addressable market, sustained revenue optionality, and clearer commercialization pathways over the next 2–6 months.
Broad Pipeline With Multiple Near‑term CatalystsA deep, diversified clinical portfolio with several near-term readouts spreads development risk and creates multiple opportunities to generate durable value. Positive pivotal data would enable label expansion and partner monetization, while the breadth supports longer-term product flow even if individual trials vary.
Material Balance Sheet Strengthening And Partner RevenueA significantly strengthened cash position and recent sizeable financings materially extend runway for R&D, pivotal readouts and commercialization. Recurring collaboration/licensing payments and milestone potential further diversify funding sources and reduce near‑term dilution and execution risk.
Bears Say
Volatile Financials And Higher LeverageRecent swings from episodic collaboration revenue to sizable losses and higher leverage weaken financial flexibility. Negative TTM cash flow and elevated debt-to-equity increase refinancing and funding risk, making sustained investment through pivotal readouts and commercialization more contingent on capital markets or partner payments.
Dependence On Upcoming Clinical/regulatory ReadoutsThe company’s near-term commercial and label expansion trajectory hinges on several pivotal blinded readouts. Failures or ambiguous results would materially impair approval timelines and partner milestones, concentrating downside risk and potentially delaying revenue scale and strategic partnerships over the medium term.
Nascent Product Sales And Commercialization UncertaintyProduct revenue is still embryonic and pricing/gross‑to‑net visibility is limited. Lower competitor pricing and withheld gross‑to‑net assumptions create uncertainty in realized revenue per script and reimbursement dynamics, making near‑term commercial profitability and payer uptake outcomes less predictable.
Arrowhead Pharmaceuticals News
ARWR FAQ
What was Arrowhead Pharmaceuticals, Inc.’s price range in the past 12 months?
Arrowhead Pharmaceuticals, Inc. lowest stock price was $14.30 and its highest was $87.83 in the past 12 months.
What is Arrowhead Pharmaceuticals, Inc.’s market cap?
Arrowhead Pharmaceuticals, Inc.’s market cap is $10.47B.
When is Arrowhead Pharmaceuticals, Inc.’s upcoming earnings report date?
Arrowhead Pharmaceuticals, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 17 days.
How were Arrowhead Pharmaceuticals, Inc.’s earnings last quarter?
Arrowhead Pharmaceuticals, Inc. released its earnings results on May 07, 2026. The company reported -$0.93 earnings per share for the quarter, beating the consensus estimate of -$1.095 by $0.165.
Is Arrowhead Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Arrowhead Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Arrowhead Pharmaceuticals, Inc. pay dividends?
Arrowhead Pharmaceuticals, Inc. does not currently pay dividends.
What is Arrowhead Pharmaceuticals, Inc.’s EPS estimate?
Arrowhead Pharmaceuticals, Inc.’s EPS estimate is -1.23.
How many shares outstanding does Arrowhead Pharmaceuticals, Inc. have?
Arrowhead Pharmaceuticals, Inc. has 140,857,030 shares outstanding.
What happened to Arrowhead Pharmaceuticals, Inc.’s price movement after its last earnings report?
Arrowhead Pharmaceuticals, Inc. reported an EPS of -$0.93 in its last earnings report, beating expectations of -$1.095. Following the earnings report the stock price went down -6.748%.
Which hedge fund is a major shareholder of Arrowhead Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in ARWR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arrowhead Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$91.00 (30.92% Upside)
$91.00 (30.92% Upside)
Blogger Sentiment
Bullish
ARWR Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 3.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
294.16%
12-Months-Change
Fundamentals
Return on Equity
-55.45%
Trailing 12-Months
Asset Growth
44.15%
Trailing 12-Months
Company Description
Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
ARWR Stock 12 Month Forecast
Average Price Target
$91.00
▲(30.92% Upside)
Technical Analysis
Ownership Overview
3.66% Insiders
19.74% Mutual Funds
0.18% Other Institutional Investors
50.99% Public Companies and
Individual Investors